Research Analysts Set Expectations for Omnicell Q1 Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Stock analysts at Zacks Research decreased their Q1 2028 EPS estimates for shares of Omnicell in a report released on Friday, August 14th. Zacks Research analyst Team now anticipates that the company will earn $0.40 per share for the quarter, down from their prior forecast of $0.41. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.30 per share.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The company had revenue of $312.21 million for the quarter, compared to analyst estimates of $310.21 million. During the same period in the previous year, the business posted $0.45 earnings per share. Omnicell’s quarterly revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS.

Several other research analysts also recently weighed in on OMCL. Wells Fargo & Company lowered their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. KeyCorp cut their price target on Omnicell from $70.00 to $65.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Craig Hallum reaffirmed a “buy” rating and set a $55.00 price target on shares of Omnicell in a report on Wednesday, April 29th. Weiss Ratings reissued a “hold (c-)” rating on shares of Omnicell in a research note on Tuesday, August 4th. Finally, Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Omnicell presently has a consensus rating of “Moderate Buy” and an average price target of $57.86.

Omnicell Stock Performance

Shares of OMCL stock opened at $36.03 on Tuesday. The stock’s 50-day moving average price is $40.60 and its 200 day moving average price is $39.98. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.64 billion, a PE ratio of 42.89, a price-to-earnings-growth ratio of 1.01 and a beta of 0.98. Omnicell has a 52-week low of $29.06 and a 52-week high of $55.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in Omnicell in the second quarter worth $313,044,000. Dimensional Fund Advisors LP grew its stake in shares of Omnicell by 6.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock worth $81,791,000 after purchasing an additional 137,834 shares during the period. Wellington Management Group LLP grew its stake in shares of Omnicell by 156.4% during the 4th quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after purchasing an additional 1,265,818 shares during the period. Lazard Asset Management LLC increased its holdings in shares of Omnicell by 3.8% in the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after purchasing an additional 62,733 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Omnicell by 2.0% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock valued at $47,095,000 after purchasing an additional 27,497 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.